TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
-5.96%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$256M
AUM Growth
+$256M
(+2.6%)
Cap. Flow
+$29.5M
Cap. Flow
% of AUM
11.53%
Top 10 Holdings %
Top 10 Hldgs %
54.27%
Holding
60
New
20
Increased
9
Reduced
8
Closed
21
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$20.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$15M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$13.9M |
| 4 |
Celldex Therapeutics
CLDX
|
$13.1M |
| 5 |
Protagonist Therapeutics
PTGX
|
$10.8M |
Top Sells
| 1 |
AbbVie
ABBV
|
$24.4M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$15M |
| 3 |
Eli Lilly
LLY
|
$10.6M |
| 4 |
United Therapeutics
UTHR
|
$9.92M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$9.27M |
Sector Composition
| 1 | Healthcare | 93.68% |
| 2 | Consumer Staples | 3.25% |
| 3 | Financials | 0.07% |
| 4 | Real Estate | 0.04% |
| 5 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $20.3M | 7.95% | +130,678 | New | +$20.3M |
|
|
2
Protagonist Therapeutics
PTGX
$3.67B
| $18.2M | 7.12% | 769,250 +455,321 | +145% | +$10.8M |
|
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $15M | 5.86% | +21,477 | New | +$15M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $13.9M | 5.44% | +132,332 | New | +$13.9M |
|
|
5
Celldex Therapeutics
CLDX
$1.47B
| $13.1M | 5.1% | +383,319 | New | +$13.1M |
|
6
Edwards Lifesciences
EW
$47.8B
| $12.6M | 4.91% | 106,790 -40,606 | -28% | -$4.78M |
|
7
Kezar Life Sciences
KZR
$28.9M
| $12.1M | 4.75% | 730,897 -1,618 | -0.2% | -$26.9K |
|
|
8
Eli Lilly
LLY
$657B
| $11.9M | 4.65% | 41,610 -36,918 | -47% | -$10.6M |
|
9
argenx
ARGX
$43.6B
| $11.3M | 4.42% | 35,880 -12,467 | -26% | -$3.93M |
|
10
Adicet Bio
ACET
$59.9M
| $10.4M | 4.08% | 523,256 -60,146 | -10% | -$1.2M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $9.06M | 3.54% | 406,733 +193,559 | +91% | +$4.31M |
|
12
Bristol-Myers Squibb
BMY
$96B
| $8.97M | 3.5% | +122,817 | New | +$8.97M |
|
|
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.49M | 3.32% | +504,371 | New | +$8.49M |
|
14
Stevanato
STVN
$6.28B
| $8.39M | 3.28% | 416,920 +190,220 | +84% | +$3.83M |
|
15
The Beauty Health Co
SKIN
$264M
| $8.33M | 3.25% | 493,301 -12,979 | -3% | -$219K |
|
16
Evolent Health
EVH
$1.12B
| $7.48M | 2.92% | 231,499 +6,402 | +3% | +$207K |
|
17
Exelixis
EXEL
$10.1B
| $7.46M | 2.91% | +329,068 | New | +$7.46M |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.43M | 2.9% | 296,327 -139,973 | -32% | -$3.51M |
|
19
Fate Therapeutics
FATE
$120M
| $7.38M | 2.88% | 190,345 +48,313 | +34% | +$1.87M |
|
|
BLU
20
DELISTED
BELLUS Health Inc.
BLU
| $6.95M | 2.71% | 1,009,615 +33,682 | +3% | +$232K |
|
21
Aldeyra Therapeutics
ALDX
$351M
| $6.43M | 2.51% | +1,447,445 | New | +$6.43M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.14M | 2.4% | 51,750 +27,404 | +113% | +$3.25M |
|
|
RXDX
23
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $5.63M | 2.2% | +149,066 | New | +$5.63M |
|
24
BioNTech
BNTX
$24B
| $5.27M | 2.06% | +30,923 | New | +$5.27M |
|
25
Revolution Medicines
RVMD
$7.1B
| $4.35M | 1.7% | +170,455 | New | +$4.35M |
|